Fluoresceinnatrium Minims 20 mg/ ml Norge - norsk - Statens legemiddelverk

fluoresceinnatrium minims 20 mg/ ml

bausch + lomb ireland limited - fluoresceinnatrium - Øyedråper, oppløsning - 20 mg/ ml

Anatera 100 mg/ ml Norge - norsk - Statens legemiddelverk

anatera 100 mg/ ml

alcon nordic a/s - fluoresceinnatrium - injeksjonsvæske, oppløsning - 100 mg/ ml

Combiflure 1.25 mg/ ml / 3 mg/ ml Norge - norsk - Statens legemiddelverk

combiflure 1.25 mg/ ml / 3 mg/ ml

santen oy - fluoresceinnatrium / oksybuprokainhydroklorid - Øyedråper, oppløsning - 1.25 mg/ ml / 3 mg/ ml

Lucentis Den europeiske union - norsk - EMA (European Medicines Agency)

lucentis

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - Øyemidler - lucentis er angitt i voksne for:behandling av neovascular (våt) aldersrelatert makuladegenerasjon (amd)behandling av synshemming på grunn av choroidal neovascularisation (cnv)behandling av synshemming på grunn diabetiker macular ødemer (dme)behandling av synshemming på grunn av flekker ødemer sekundært til retinal vene okklusjon (gren rvo eller sentrale rvo).

Byooviz Den europeiske union - norsk - EMA (European Medicines Agency)

byooviz

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - Øyemidler - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ximluci Den europeiske union - norsk - EMA (European Medicines Agency)

ximluci

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - Øyemidler - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ranivisio Den europeiske union - norsk - EMA (European Medicines Agency)

ranivisio

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - Øyemidler - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Latanoprost Sandoz 50 mikrog/ ml Norge - norsk - Statens legemiddelverk

latanoprost sandoz 50 mikrog/ ml

sandoz - københavn - latanoprost - Øyedråper, oppløsning - 50 mikrog/ ml

Latiotim 50 mikrog/ ml / 5 mg/ ml Norge - norsk - Statens legemiddelverk

latiotim 50 mikrog/ ml / 5 mg/ ml

sandoz (2) - latanoprost / timololmaleat - Øyedråper, oppløsning - 50 mikrog/ ml / 5 mg/ ml

Monoprost 50 mikrog/ ml Norge - norsk - Statens legemiddelverk

monoprost 50 mikrog/ ml

laboratoires théa s.a.s - latanoprost - Øyedråper, oppløsning - 50 mikrog/ ml